Cryoport, Inc. (CYRX)
| Market Cap | 880.28M +83.9% |
| Revenue (ttm) | 186.45M +12.1% |
| Net Income | -45.39M |
| EPS | -0.91 |
| Shares Out | 50.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 732,391 |
| Open | 17.29 |
| Previous Close | 17.41 |
| Day's Range | 17.11 - 17.56 |
| 52-Week Range | 7.61 - 17.98 |
| Beta | 1.90 |
| Analysts | Strong Buy |
| Price Target | 19.33 (+11.22%) |
| Est. Earnings | Nov 3, 2026 |
About CYRX
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The comp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CYRX stock is "Strong Buy." The 12-month stock price target is $19.33, which is an increase of 11.22% from the latest price.
News
Cryoport management to meet with BTIG
Healthcare IT & Digital Health Analyst Larsen holds a Field Trip to New York on October 7 and New Jersey on October 8 hosted by BTIG.
Cryoport price target raised to $19 from $15 at Needham
Needham raised the firm’s price target on Cryoport (CYRX) to $19 from $15 and keeps a Buy rating on the shares. The company’s Q2 sales beat consensus and management reiterated…
Cryoport price target raised to $16 from $12 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Cryoport (CYRX) to $16 from $12 and keeps a Buy rating on the shares.
Cryoport price target raised to $21 from $15 at Roth Capital
Roth Capital analyst Richard Baldry raised the firm’s price target on Cryoport (CYRX) to $21 from $15 and keeps a Buy rating on the shares. Cryoport delivered a strong Q2…
Cryoport Earnings Call Transcript: Q2 2026
Q2 2026 saw $49M in revenue, 15% growth in Life Sciences Services, and positive Adjusted EBITDA. Guidance for 2026 is reaffirmed at $192M-$196M, with strong demand, new product launches, and operational milestones supporting sustainable growth.
Cryoport Slides: Q2 2026
Cryoport has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Cryoport Earnings release: Q2 2026
Cryoport released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Cryoport Quarterly report: Q2 2026
Cryoport has published its Q2 2026 quarterly earnings report on August 6, 2026.
Cryoport reports Q2 EPS (20c), consensus (18c)
Reports Q2 revenue $49M, consensus $48.21M. Jerrell Shelton, CEO of Cryoport (CYRX), commented, “Our revenue momentum over the past several periods continued into the second quarter, with total revenu...
Cryoport Reports Second Quarter 2026 Financial Results
Second quarter revenue grew 8% year-over-year to $49.0 million Life Sciences Services revenue increased 15% year-over-year BioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global ...
Cryoport price target raised to $25 from $17 at BTIG
BTIG raised the firm’s price target on Cryoport (CYRX) to $25 from $17 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026
NASHVILLE, Tenn., July 23, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for t...
Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR...
Cryoport management to meet with Craig-Hallum
Meeting to be held in Denver on June 22 hosted by Craig-Hallum.
Cryoport price target raised to $13.50 from $11 at Jefferies
Jefferies analyst Matthew Stanton raised the firm’s price target on Cryoport (CYRX) to $13.50 from $11 and keeps a Hold rating on the shares. The firm said it came away…
Cryoport Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and an equity plan amendment. All proposals passed, with official results to be filed in a Form 8-K within four business days.
Cryoport price target raised to $20 from $15 at Craig-Hallum
Craig-Hallum analyst Matthew Hewitt raised the firm’s price target on Cryoport (CYRX) to $20 from $15 and keeps a Buy rating on the shares. The firm believes growth should accelerate…
Cryoport Slides: Corporate presentation
Cryoport has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Cryoport price target raised to $17 from $15 at KeyBanc
KeyBanc analyst Paul Knight raised the firm’s price target on Cryoport (CYRX) to $17 from $15 and keeps an Overweight rating on the shares. The firm believes the company’s revenue…
Cryoport price target raised to $15 from $13 at Needham
Needham raised the firm’s price target on Cryoport (CYRX) to $15 from $13 and keeps a Buy rating on the shares.
Cryoport price target raised to $17 from $15 at BTIG
BTIG raised the firm’s price target on Cryoport (CYRX) to $17 from $15 and keeps a Buy rating on the shares. The firm is citing the company’s Q1 earnings beat…
Cryoport price target raised to $12 from $11 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Cryoport (CYRX) to $12 from $11 and keeps a Buy rating on the shares. After what the firm calls “a…
Cryoport Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 16% year-over-year to $47.8M, with strong double-digit gains across both Life Sciences Services and Products. Full-year guidance was raised to $192–$196M, and positive adjusted EBITDA is expected in the second half, driven by robust demand and operational improvements.
Cryoport Slides: Q1 2026
Cryoport has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 4, 2026.
Cryoport Earnings release: Q1 2026
Cryoport released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.